Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

IMI Graham Hughes


Published on

  • Be the first to comment

  • Be the first to like this

IMI Graham Hughes

  1. 1. Innovative Medicines Initiative Graham Hughes UK National Contact Point Health "By joining the best academic teams with high-level industry scientists, IMI is building the research capacity needed to cure the major diseases of our time." Michel Goldman, IMI Executive Director
  2. 2. Innovative Medicines Initiative
  3. 3. IMI in the Health Theme Activity 1: Biotechnology, generic tools & technologies for health Activity 2: Translating research for human health Activity 3: Optimising the delivery of health care cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender -related health issues Activity 4: Support actions & response to policy needs The Innovative Medicines Initiative
  4. 4. Why is IMI needed?
  5. 5. What are the Expected Results? <ul><li>To modernise the development process of medicines; </li></ul><ul><li>To drive the development of innovative medicines with a high level of safety and efficacy, for millions of patients; </li></ul><ul><li>To generate more and better quality jobs for scientists , reversing the European brain drain; </li></ul><ul><li>To enhance European expertise and know-how in new technologies to attract pharmaceutical R&D investment to Europe; </li></ul><ul><li>To create a stronger competitive advantage for smaller companies (SMEs, spin-offs and start-ups) and public organisations by collaborating with a multitude of stakeholders. </li></ul>
  6. 6. How to Achieve Results <ul><li>Support “pre-competitive pharmaceutical research and development ” – accelerate the development of safer and more effective medicines for patients </li></ul><ul><li>Modernization of the drug development process , via new approaches, methods and technologies, better use of research results and data and more skilled staff </li></ul><ul><li>Foster collaboration between stakeholders , e.g industry, academia, patient organisations, public authorities (inc regulators) , clinical centres etc </li></ul><ul><li>Addresses the challenges in the development process of drugs rather than aiming to deliver new medicine s </li></ul>
  7. 7. How is it funded? <ul><li>EFPIA members fully fund their own participation and provide R&D resources such as staff, laboratories, materials and clinical research . </li></ul><ul><li>EU funds exclusively public organisations or nonprofit organisations and small and medium-sized enterprises (SMEs). </li></ul>
  8. 8. IMI Governance
  9. 9. IMI Research Agenda
  10. 10. IMI Projects: Key facts <ul><li>Open and competitive calls with a peer review process by independent experts </li></ul><ul><li>Average project size €15 - 20 million </li></ul><ul><li>Average consortium size in the range of: </li></ul><ul><ul><li>9 – 16 pharmaceutical companies </li></ul></ul><ul><ul><li>9 – 37 academic, SME, regulatory, patient organisations </li></ul></ul><ul><li>EU funding to academic, SME and other partners is </li></ul><ul><ul><li>75% of total eligible research costs </li></ul></ul><ul><ul><li>100% of total eligible management and training costs </li></ul></ul><ul><li>Total eligible costs include direct eligible costs plus 20% overheads </li></ul>
  11. 11. IMI Research Consortium
  12. 12. IMI Call Process
  13. 13. 1 st Call (2008) 15 Projects 395 teams 24 SMEs 11 patient organisations EU Budget = €281 Million <ul><li>Pillars : </li></ul><ul><li>Drug Safety </li></ul><ul><li>Education and Training </li></ul><ul><li>Thematic Areas </li></ul><ul><li>Neurosciences </li></ul><ul><li>Diabetes </li></ul><ul><li>Lung Disease </li></ul>UK SMEs CXR Biosciences Psynova Neurotech Synairgen Reasearch Choice Pharma
  14. 14. 2 nd Call (2009) <ul><li>Projects start March 2011 </li></ul><ul><li>8 Projects </li></ul><ul><li>EFPIA teams </li></ul><ul><li>103 Academic teams </li></ul><ul><li>23 SMEs </li></ul><ul><li>2 patient organisations </li></ul>EU Budget = €172 Million <ul><li>Pillars : </li></ul><ul><li>Drug Efficacy </li></ul><ul><li>Knowledge Management </li></ul><ul><li>Thematic Areas </li></ul><ul><li>Cancer </li></ul><ul><li>Rheumatoid Arthritis </li></ul><ul><li>Infectious Disease </li></ul>UK SMEs Cyprotex Discovery Mango Business Solutions Simcyp Ltd Assero Ltd Academic Concept Knowledge Ltd
  15. 15. 3 rd Call (2010) Launched 22 Oct 2010 EoI Deadline 18 Jan 2011 Evaluations March/April EU Budget = €114 Million <ul><li>Pillars : </li></ul><ul><li>Drug Safety </li></ul><ul><li>Drug efficacy </li></ul><ul><li>Education and Training </li></ul><ul><li>Thematic Areas </li></ul><ul><li>Inflammatory Disease </li></ul><ul><li>Neurological Disease </li></ul><ul><li>Infectious Disease </li></ul><ul><li>Diabetes </li></ul>
  16. 16. 4 th Call
  17. 17. Launch Date 17 th June 2011
  18. 18. Support <ul><li> </li></ul>